Dr. Hofmeister Discusses Checkpoint Inhibitors in Myeloma
In Partnership With:
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.
Craig Hofmeister, MD, associate professor, The Ohio State University Comprehensive Cancer Center, discusses checkpoint inhibitors in multiple myeloma.
A trial of durvalumab (Imfinzi) and lenalidomide (Revlimid) with and without low-dose dexamethasone in patients with newly diagnosed multiple myeloma, and three other studies exploring durvalumab in multiple myeloma—MEDI4736-MM-001, MEDI4736-MM-003, and MEDI4736-MM-005—were placed on partial hold earlier in 2017.
Hofmeister hopes that with further testing they will be incorporated as relapsed, and ultimately upfront therapy for patients with multiple myeloma.
